This review delves into the evolving realm of liquid biopsy, a groundbreaking tool with the potential to transform cancer care. Researchers explored its clinical applications in the context of surgical patients. While circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have been studied extensively, their practical use in surgical settings is not yet fully defined. They show promise in detecting disease progression, guiding systemic therapy, and predicting recurrence, particularly for early-stage cases. However, there is still much to learn, and surgeons need to actively engage in clinical trials to advance this game-changing technology.
Journal Article by Mahuron KM and Fong Y in JAMA Surg